

# THE ROLE OF OMEGA-3 FATTY ACIDS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

DARIJA VRANEŠIĆ BENDER

University Hospital Centre Zagreb | Croatia

## REFERENCES

1. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism*. 2016;65(8):1038-48.
2. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. *Liver Int*. 2017;37 Suppl 1:81-84.
3. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. *Lancet Diabetes Endocrinol*. 2014;2(11):901-10.
4. Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. *Redox Biol*. 2018;15:467-479.
5. Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. *JHEP Rep*. 2019;1(6):468-479.
6. Nobili V, Alisi A, Musso G, Scorletti E, Calder PC, Byrne CD. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. *Crit Rev Clin Lab Sci*. 2016;53(2):106-20.
7. Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids. *World J Gastroenterol*. 2014;20(7):1746-55.
8. Harris WS & Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? *Prev Med* 2004 39, 212–220.
9. Hals, P.A., Wang, X., Xiao, Y.F. Effects of a purified krill oil phospholipid rich in long-chain omega-3 fatty acids on cardiovascular disease risk factors in non-human primates with naturally occurring diabetes type-2 and dyslipidemia. *Lipids Health Dis*. 2017; 16 (1):11.
10. Vranešić Bender D, Nutrizio M, Jošić M, Ljubas Kelečić D, Karas I, Premužić M, Domislović V, Rotim C, Krznarić Ž. Nutritional status and nutrition quality in patients with non-alcoholic fatty liver disease. *Acta Clin Croat* 2017; 56(4): 625-634.
11. Bullón-Vela V, Abete I, Tur JA, Pintó X, Corbella E, Martínez-González MA, Toledo E, Corella D, Macías M, Tinahones F, Fitó M, Estruch R, Ros E, Salas-Salvadó J, Daimiel L, Zulet MA, Martínez JA; PREDIMED Plus investigators. Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features. *Nutrition*. 2020; 71:110620.
12. Sofi, F., Casini, A. Mediterranean diet and non-alcoholic fatty liver disease: New therapeutic option around the corner? *World J Gastroenterol*. 2014; 20 (23), 7339-7346.
13. Baratta, F., Pastori, D., Polimeni, L., Bucci, T., Ceci, F., Calabrese, C., Ernesti, I., Pannitteri, G., Violi, F., Angelico, F., Del Ben, M. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. *Am J Gastroenterol*. 2017; 112 (12), 1832-1839.
14. Cicero AFG, Colletti A, Bellentani S. NutraceuTical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. *Nutrients*. 2018; 23;10(9).
15. Milic S, Mikolasevic I, Krznaric-Zrnac I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. *Drug Des Devel Ther*. 2015; 20;9:4835-45.
16. Byrne CD, Targher G. NAFLD: a multisystem disease. *J Hepatol*. 2015;62(1 Suppl):S47-64.

17. Pettinelli P, Del PT, Araya J, et al. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. *Biochim Biophys Acta* 2009;1792:1080–6.
18. Calder P. Marine omega-3 fatty acids and inflammation. *J Lipid Nutr* 2010;19:233–44.
19. Lu, W., Li, S., Li, J., Wang, J., Zhang, R., Zhou, Y., Yin, Q., Zheng, Y., Wang, F., Xia, Y., Chen, K., Liu, T., Lu, J., Zhou, Y., Guo, C. Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. *Gastroenterol Res Pract.* 2016; 1459790. doi: 10.1155/2016/1459790.
20. Parker HM, O'Connor HT, Keating SE, Cohn JS, Garg ML, Caterson ID, George J, Johnson NA. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study. *Br J Nutr.* 2015;114(5):780-7.
21. Vranesic Bender D, Zupcic M, Hok M, Delas I, Barisic A, Ljubas Kelecic D, Karas I, Premuzic M, Krznaric Z. Effects of krill oil on omega-3 index and cardiometabolic risk factors in patients with non-alcoholic fatty liver disease (NAFLD): pilot randomized double-blind trial. *Clin Nutr* 2019; 38; S45.